{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"description":"Assessment of the toxicities resulting from administration of combinations of thalidomide, bortezomib and melphalan","groups":[{"description":"Phase I - Thalidomide Dose Level 600 mg","id":"OG000","title":"Phase I - Thalidomide Dose Level 600 mg"},{"description":"Phase I - Thalidomide Dose Level 800 mg","id":"OG001","title":"Phase I - Thalidomide Dose Level 800 mg"},{"description":"Phase I - Thalidomide Dose Level 1000 mg","id":"OG002","title":"Phase I - Thalidomide Dose Level 1000 mg"},{"description":"Phase 2 Dose Level 1000 mg of Thalidomide","id":"OG003","title":"Phase 2"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Patients will be hospitalized or in the outpatient transplant facility until engraftment and resolution of serious adverse events, a median of 16 (range, 11-24) days","title":"Toxicity Assessment","type":"SECONDARY","unitOfMeasure":"Serious Adverse Events"}